Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 1/20 | 0.31 |
| ▸ | GRM6 | O15303 | 2/20 | 0.31 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.31 |
| ▸ | GRM3 | Q14832 | 2/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4871730 | 0.75 | APLNR (0.33) | APLNRGRM6GRM2GRM3CYP1A2 | |
| SCHEMBL28234755 | 0.74 | CYP1A2 (0.50) | CYP1A2 | |
| SCHEMBL30823593 | 0.73 | FFAR3 (0.48) | APLNRGRM6GRM2GRM3CYP1A2 | |
| SCHEMBL28234773 | 0.71 | CYP2C19 (0.36) | CYP1A2 | |
| SCHEMBL22341308 | 0.67 | CYP1A2 (0.32) | CYP1A2 | |
| Bicarbonate SCHEMBL9238265 | 0.67 | CA1 (0.39) | APLNRCYP1A2 | |
| SCHEMBL6377756 | 0.65 | CYP1A2 (0.60) | CYP1A2 | |
| SCHEMBL19133290 | 0.65 | ALDH1A1 (0.39) | — | |
| SCHEMBL7772766 | 0.65 | CYP1A2 (0.60) | CYP1A2 | |
| SCHEMBL1635240 | 0.65 | SLC6A4 (0.35) | APLNRGRM6GRM2GRM3CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190016745-A1 | AMINOGLYCOSIDE DERIVATIVES AND USES THEREOF IN TREATING MICROBIAL INFECTIONS | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) | 2019-01-17 | — | — | US | claimed |
| EP-3400231-A1 | AMINOGLYCOSIDE DERIVATIVES AND USES THEREOF IN TREATING MICROBIAL INFECTIONS | Technion Research & Development Foundation Limited (IL) | 2018-11-14 | — | — | EP | claimed |
| US-20180282361-A1 | AMINOGLYCOSIDE DERIVATIVES AND USES THEREOF IN TREATING GENETIC DISORDERS | ELOXX PHARMACEUTICALS LTD. (IL) | 2018-10-04 | — | — | US | claimed |
| CN-108350014-A | Aminoglycoside derivatives and their use in the treatment of genetic disorders | ELOXX制药有限公司 | 2018-07-31 | — | — | CN | claimed |
| EP-3344641-A1 | AMINOGLYCOSIDE DERIVATIVES AND USES THEREOF IN TREATING GENETIC DISORDERS | Eloxx Pharmaceuticals Ltd. (IL) | 2018-07-11 | — | — | EP | claimed |
| WO-2017118967-A1 | AMINOGLYCOSIDE DERIVATIVES AND USES THEREOF IN TREATING MICROBIAL INFECTIONS | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) | 2017-07-13 | — | — | WO | claimed |
| WO-2017037719-A1 | AMINOGLYCOSIDE DERIVATIVES AND USES THEREOF IN TREATING GENETIC DISORDERS | ELOXX PHARMACEUTICALS LTD. (IL) | 2017-03-09 | — | — | WO | claimed |
| US-11613551-B2 | Aminoglycoside derivatives and uses thereof in treating genetic disorders | ELOXX PHARMACEUTICALS LTD. (IL) | 2023-03-28 | — | — | US | disclosed |
| CN-114957357-A | Aminoglycoside derivatives and their use in the treatment of genetic disorders | ELOXX制药有限公司 | 2022-08-30 | — | — | CN | disclosed |
| CN-108350014-B | Aminoglycoside derivatives and their use in the treatment of genetic disorders | ELOXX制药有限公司 | 2022-06-10 | — | — | CN | disclosed |
| US-20210300958-A1 | AMINOGLYCOSIDE DERIVATIVES AND USES THEREOF IN TREATING GENETIC DISORDERS | ELOXX PHARMACEUTICALS LTD. (IL) | 2021-09-30 | — | — | US | disclosed |
| US-10899785-B2 | Aminoglycoside derivatives and uses thereof in treating genetic disorders | ELOXX PHARMACEUTICALS LTD. (IL) | 2021-01-26 | — | — | US | disclosed |
| US-20190016746-A1 | AMINOGLYCOSIDE DERIVATIVES AND USES THEREOF IN TREATING GENETIC DISORDERS | ELOXX PHARMACEUTICALS LTD. (IL) | 2019-01-17 | — | — | US | disclosed |
| US-4064341-A | ANTIBIOTIC | THE UPJOHN COMPANY (US) | 1977-12-20 | — | — | US | disclosed |
| US-4038478-A | ANTIBACTERIAL AGENTS | THE UPJOHN COMPANY (US) | 1977-07-26 | — | — | US | disclosed |
| US-4031304-A | Process for preparing lincomycin derivatives | THE UPJOHN COMPANY (US) | 1977-06-21 | — | — | US | disclosed |
| US-3996205-A | BACTERICIDES | THE UPJOHN COMPANY (US) | 1976-12-07 | — | — | US | disclosed |
| US-3984393-A | BACTERICIDES | THE UPJOHN COMPANY (US) | 1976-10-05 | — | — | US | disclosed |
| US-3976667-A | ANTIBIOTIC | THE UPJOHN COMPANY (US) | 1976-08-24 | — | — | US | disclosed |
| US-3944562-A | ANTIBIOTIC | THE UPJOHN COMPANY (US) | 1976-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210300958-A1 | AMINOGLYCOSIDE DERIVATIVES AND USES THEREOF IN TREATING GENETIC DISORDERS | UPF1, AARS1, NUDT21 | APLNR 1069/4885GRM6 4235/4885GRM2 4388/4885 |
| US-20190016746-A1 | AMINOGLYCOSIDE DERIVATIVES AND USES THEREOF IN TREATING GENETIC DISORDERS | UPF1, AARS1, GET3 | APLNR 991/4885GRM6 4063/4885GRM2 4478/4885 |
| US-20190016745-A1 | AMINOGLYCOSIDE DERIVATIVES AND USES THEREOF IN TREATING MICROBIAL INFECTIONS | ALPI, MGAM, AASDHPPT | APLNR 776/4885GRM6 4589/4885GRM2 4694/4885 |
| US-11613551-B2 | Aminoglycoside derivatives and uses thereof in treating genetic disorders | UPF1, AARS1, NUDT21 | APLNR 1069/4885GRM6 4235/4885GRM2 4388/4885 |
| US-10899785-B2 | Aminoglycoside derivatives and uses thereof in treating genetic disorders | UPF1, AARS1, NUDT21 | APLNR 1069/4885GRM6 4235/4885GRM2 4388/4885 |
| US-20180282361-A1 | AMINOGLYCOSIDE DERIVATIVES AND USES THEREOF IN TREATING GENETIC DISORDERS | UPF1, AARS1, NUDT21 | APLNR 1069/4885GRM6 4235/4885GRM2 4388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.